Ziopharm Initiates Phase II Liver Cancer Drug Trial
Posted on: Friday, 11 May 2007, 09:00 CDT
US biopharmaceutical company Ziopharm Oncology has begun dosing of the first patient in a phase II trial of its investigational drug for the treatment of patients with primary liver cancer.
Primary liver cancer is one of the most commonly occurring cancers in the world. The study will take place at five major US liver cancer treatment centers including sites in New York, Boston, Miami, Seattle, and Atlanta.
Brian Schwartz, chief medical officer at Ziopharm, said: "Liver cancer is one of the most difficult cancers to manage. We look forward to seeing if this novel form of organic arsenical will give clinicians an additional treatment option."
In addition to the phase II liver cancer trial, the company is conducting phase II studies with ZIO-101 in advanced multiple myeloma and diverse hematological cancers, including acute myelogenous leukemia, myelodysplastic syndrome and acute promyelocytic leukemia.
Source: Datamonitor
Related Articles
- Bayer and Onyx Launch Educational Program to Raise Awareness About Liver Cancer and Its Risk Factors
- ThermoDox(R) Liver Cancer Study Phase I Results to Be Presented at ILCA Conference 2008
- Protherics Initiates Phase IIa Liver Cancer Study
- BioAlliance Pharma Suspends the Phase II/III Trial of Doxorubicin Transdrug(R) in Primary Liver Cancer
- Phase II Study of IMC-A12 for Advanced Liver Cancer Opens for Patient Enrollment
- Progen Initiates Phase III Liver Cancer Study
- ZIOPHARM Treats First Patient in Phase II ZIO-101 Liver Cancer Trial
- pSivida Announces BrachySil(TM) Phase IIb Clinical Trials for Liver Cancer Commence Following Approval By HSA
- BioAlliance Pharma Receives U.S. FDA Orphan Drug Designation for Doxorubicin Transdrug for Treatment of Primary Liver Cancer
 |
 |
User Comments (0)
RSS Feeds